Tobira Therapeutics, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2015 12 months to Dec 31, 2015	FY2014 12 months to Dec 31, 2014	FY2013 12 months to Dec 31, 2013
Operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation
Amortization of patents and licenses
Depreciation and amortization
Stock-based compensation
Loss on disposal of property and equipment
Other
Loss on disposal of assets
Amortization of debt discount
Change in fair value of preferred stock warrant liabilities
Noncash interest expense on convertible notes
Amortization of beneficial conversion feature
Amortization of debt issuance costs
Deferred income taxes
Impairment of intangible assets
Impairment of clinical trial supplies
Accrued final bank fee
Change in assets and liabilities:
Prepaid expenses
Other assets
Other non-current assets
Accounts payable
Accrued expenses
Prepaid expenses and other assets
Restricted cash
Accounts payable and accrued expenses
Deferred rent
Net cash used in operating activities
Change in restricted cash
Investing activities
Cash received from Merger
Purchase of property and equipment
Patent and license acquisition costs
Proceeds received from sale of patents
Net cash used in investing activities
Net cash provided by (used in) investing activities
Financing activities
Proceeds from issuance of common stock, net
Proceeds from sale of preferred stock, net of issuance costs
Proceeds from borrowings on bank loan
Repayment of borrowings on bank loan
Payment of bank origination fee
Payment of debt issuance costs
Proceeds from issuance of common stock in IPO, net of underwriting discounts
Payment of IPO costs
Proceeds from issuance of common stock upon exercise of options and warrants
Costs from issuance of Series F
Proceeds from exercise of warrants
Proceeds from borrowings in connection with term loan, net
Proceeds from convertible notes, related party
Payments on term loan
Payments on capital lease obligations
Net cash provided by financing activities
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Supplemental disclosure of cash flow information
Cash paid for interest
Noncash activities:
Exchange of common stock for convertible preferred stock, net of issuance costs
Fair value of Series F Preferred Stock beneficial conversion feature
Accretion of deemed dividend on Series F Convertible Preferred Stock
Conversion of convertible notes and interest to common stock
Conversion of preferred stock to common stock
Series A and B Preferred Stock
Convertible Preferred Stock Series F
Total conversion of preferred stock to common stock
Issuance of common stock in connection with Merger
Financial Advisors
Total issuance of common stock in connection with Merger
Issuance of warrants in connection with term loan and convertible notes, related party
Beneficial conversion feature recognized upon conversion of convertible notes
Reclassification of warrant liability to additional paid-in capital upon conversion from warrants on convertible preferred stock to common stock
Reclassification of stock award liability from additional paid-in capital upon modification
Reclassification of stock award liability to additional paid-in capital upon expiration
Common stock vested
Landlord paid leasehold improvements
Equipment purchased under capital leases
Fair value of assets acquired and liabilities assumed in Merger:
Fair value of assets acquired
Fair value of liabilities assumed
Fair value of net assets acquired in Merger

Comments